Zeria Pharmaceutical Co., Ltd.
4559.T · JPX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.85 | -0.58 | -0.69 | 0.73 |
| FCF Yield | 0.00% | 0.00% | 0.00% | 0.00% |
| EV / EBITDA | 37.00 | 31.25 | 27.91 | 22.42 |
| Quality | ||||
| ROIC | 0.93% | 0.71% | 1.15% | 2.11% |
| Gross Margin | 72.69% | 71.38% | 73.15% | 73.65% |
| Cash Conversion Ratio | – | – | – | – |
| Growth | ||||
| Revenue 3-Year CAGR | 5.95% | 6.64% | 8.49% | 7.67% |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 6.01 | 5.21 | 4.19 | 3.46 |
| Interest Coverage | 17.93 | 12.48 | 17.21 | 35.52 |
| Efficiency | ||||
| Inventory Turnover | 0.28 | 0.33 | 0.37 | 0.37 |
| Cash Conversion Cycle | 344.24 | 325.63 | 291.60 | 276.90 |